Johnson & Johnson has announced a $5.5 billion settlement to resolve tens of thousands of lawsuits linking its talcum powder to ovarian cancer. The deal, if approved by claimants, would finally close a chapter of legal uncertainty that has weighed on the company for years.
The lawsuits centered on allegations that the company’s baby powder and other talc products were contaminated with asbestos, a known carcinogen. J&J has consistently denied these claims, asserting that its talc is safe and asbestos-free. The legal battle has been ongoing for over a decade, involving more than 50,000 cases.
The settlement plan will be executed through a subsidiary’s Chapter 11 bankruptcy filing, a strategy J&J previously attempted in 2021 and 2023 but was blocked by courts. The current proposal requires at least 75% of claimants to vote in favor. Payouts would be spread over 25 years, with the total amount reaching $5.5 billion including future claims.
If the settlement goes through, J&J would avoid years of additional trial costs and potential punitive damages. For claimants, it offers a guaranteed payout, though some may find the amount lower than what they might have received individually in court. The plan also covers current and future ovarian cancer claims, providing a comprehensive resolution.
The deal must still pass through bankruptcy court and face a claimant vote, a process expected to take several months. Legal experts say the outcome remains uncertain, especially given past judicial rejections of J&J’s bankruptcy tactics.
Affected parties include thousands of women and families affected by ovarian cancer, J&J’s shareholders, and the broader legal system, which has seen this case as a bellwether for mass tort litigation. The company’s stock rose slightly on the news, reflecting investor relief at a potential end to the litigation cloud.